Achaogen (NasdaqGM: AKAO) is a biotechnology Company focused on the development of novel antibiotics to address the rising rates of bacterial resistance. The Company is developing plazomicin, a next-generation aminoglycoside, for the treatment of complicated urinary tract infections (cUTIs), as well as a broader patient population infected with carbapenem-resistant Enterobacteriaceae (CRE). Achaogen is currently conducting the EPIC Phase III study in cUTI patients and expects to report topline results in the first quarter of 2017. Additional data from the CARE Phase III study, expected in the first half of 2017, may highlight plazomicin’s efficacy in treating a broad range of CRE infections.

Read More